Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

NCT03617731

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation Aachen, Germany
  • Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin Bad Saarow, Germany
  • Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie) Berlin, Germany
  • Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie Berlin, Germany
View all 72 locations
View Trial Details
Active, Not Recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Arizona Comprehensive Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California at San Diego La Jolla, California, United States
View all 46 locations
View Trial Details
Active, Not Recruiting

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02718833

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General/North Shore Cancer Center Danvers, Massachusetts, United States
  • Newton-Wellesley Hospital Newton, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham, Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NCT03246529

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • University of Florida Gainesville, Florida, United States
  • University of Miami Miami, Florida, United States
  • Loyola University Medical Center Chicago, Illinois, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

NCT05013190

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Anhui Cancer Hospital Hefei, Anhui, China
  • Beijing Chao-Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hospital Beijing, Beijing Municipality, China
  • Henan Province People Hospital Zhengzhou, Henan, China
View Trial Details

Related conditions